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2 
Genetic association studies have identified 215 risk loci for inflammatory bowel disease1–8, 42 
which have revealed fundamental aspects of its molecular biology.  We performed a genome-43 
wide association study of 25,305 individuals, and meta-analyzed with published summary 44 
statistics, yielding a total sample size of 59,957 subjects. We identified 25 new loci, three of 45 
which contain integrin genes that encode proteins in pathways identified as important 46 
therapeutic targets in inflammatory bowel disease. The associated variants are correlated 47 
with expression changes in response to immune stimulus at two of these genes (ITGA4, 48 
ITGB8) and at previously implicated loci (ITGAL, ICAM1). In all four cases, the expression 49 
increasing allele also increases disease risk. We also identified likely causal missense 50 
variants in the primary immune deficiency gene PLCG2 and a negative regulator of 51 
inflammation, SLAMF8. Our results demonstrate that new common variant associations 52 
continue to identify genes relevant to therapeutic target identification and prioritization. 53 
Inflammatory bowel disease (IBD) is a chronic, debilitating, disorder of the gastrointestinal tract that 54 
includes two common disease subtypes, Crohn’s disease and ulcerative colitis. Disease 55 
pathogenesis is poorly understood but is likely driven by a dysregulated immune response to 56 
unknown environmental triggers in genetically susceptible individuals. Treatment regimes often use 57 
potent immunomodulators to achieve and maintain remission of symptoms. However, patients 58 
commonly experience side effects, lose response to treatment, or develop complications of IBD, with 59 
many ultimately requiring major abdominal surgery. Previous genome-wide association studies 60 
(GWAS) and targeted follow-up using the Immunochip have been very successful at identifying 61 
genetic risk loci for IBD, but increased biological understanding has not yet had a significant impact 62 
on therapy for these disorders. 63 
In order to further expand our understanding of the biology of these disorders we carried out a 64 
GWAS of 12,160 IBD cases and 13,145 population controls of European ancestry that had not been 65 
included in any genome-wide meta-analysis of IBD to date (Supplementary Table 1, Online 66 
Methods). We imputed genotypes using a reference panel comprising whole genome sequences 67 
from 4,686 IBD cases9 and 6,285 publically available population controls10,11. Following quality 68 
control (Online Methods) we tested 9.7 million sites for association. At the 232 IBD associated SNPs 69 
in the latest meta-analysis by the International IBD Genetics Consortium1, 228 had effects in the 70 
3 
same direction in our data, 188 showed at least nominal evidence of replication (P<0.05) and none 71 
showed significant evidence of heterogeneity of effect by Cochrane’s Q test. Among these replicated 72 
loci was a genome-wide significant association on chromosome 10q25 that was only previously 73 
significantly associated with Crohn’s disease in individuals of East Asian ancestry3,7, further 74 
supporting near complete sharing of genetic risk loci across populations1. We meta-analyzed our 75 
new GWAS data with previously published summary statistics from 12,882 IBD cases and 21,770 76 
population controls imputed using the 1000 Genomes Project reference panel1 (Supplementary 77 
Figures 1-3, Supplementary Table 2). We observed inflation of the summary statistics (λGC = 1.23 78 
and 1.29 for Crohn’s and ulcerative colitis, respectively), but LD score regression demonstrated that 79 
this was due to broad polygenic signal, rather than confounding population substructure (both 80 
intercepts = 1.09, Online Methods). 81 
We identified 25 new loci at genome-wide significance (Table 1). In order to identify causal variants, 82 
genes and mechanisms, we performed a summary-statistic fine-mapping analysis on these loci, as 83 
well as 40 previously discovered loci that were genome-wide significant in our data but where fine-84 
mapping had not yet been attempted12 (Online Methods, Supplementary Table 3). In order to be 85 
confident about fine-mapping inferences, we restricted subsequent analyses to 12 signals where we 86 
had high quality imputed data for all relevant variants (Online Methods). At 6 of these 12 loci we 87 
identified a single variant with >50% probability of being causal (Table 2, Supplementary Figures 4-88 
6). Among these were two loci where a single variant had >99% probability of being causal: a 89 
missense variant predicted to affect protein function in SLAMF8, (rs34687326, p.Gly99Ser, Figure 90 
1a), and an intronic variant in the key regulator of Th17 cell differentiation, RORC13. SLAMF8 is a 91 
cell surface receptor that is expressed on activated myeloid cells and has been reported to 92 
negatively regulate inflammatory responses by inhibiting their migration to sites of inflammation14 93 
and repressing their production of reactive oxygen species (ROS)15. This, together with the 94 
observation that the risk-decreasing allele (MAF=0.1) is predicted to affect protein function 95 
(CADD=32.0, 92nd percentile of missense variants)16, suggests further experiments evaluating a 96 
possible gain-of-function mechanism may be worthwhile. RORC encodes RORγt, the master 97 
transcriptional regulator of Th17 cells13 and group 3 innate lymphoid cells17. Both of these cell types 98 
play important roles in defence at mucosal surfaces, especially in the intestine, and have been 99 
shown to contribute to the homeostasis between the intestinal immune system and gut 100 
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microbiota18,19, an equilibrium that is known to be lost in inflammatory bowel disease20. 101 
Pharmacologic inhibition of RORγt has been shown to offer therapeutic benefit in mouse models of 102 
intestinal inflammation, and reduces the frequency of Th17 cells isolated from primary intestinal 103 
samples of IBD patients21. 104 
In loci where fine-mapping was less clearly resolved, we searched for likely functional variants, 105 
observing a missense variant (CADD=16.5, 50.2% probability of causality) in PLCG2. Furthermore, 106 
after conditioning on this variant, we discovered a second, independent, likely functional 107 
(CADD=34.0, 74.6% probability of causality) missense variant in the same gene (P=2x10-8).  PLCG2 108 
encodes a phospholipase enzyme that plays a critical role in regulating immune pathway 109 
signalling22, and has previously been implicated in two autosomal dominant immune disorders. 110 
Intragenic deletions in its autoinhibitory domain cause antibody deficiency and immune dysregulation 111 
(familial cold autoinflammatory syndrome 3, MIM 614468)23 and heterozygous missense variants 112 
(e.g. p.Ser707Tyr) lead to a phenotype that includes intestinal inflammation24 (Figure 1b).  113 
A more general overlap between candidate IBD GWAS genes and Mendelian disorders of 114 
inflammation and immunity has been previously observed in 163 loci discovered at that time25. We 115 
replicated this finding in our list of 241 loci (p < 10-6, Supplementary Table 4), and observed that this 116 
enrichment is even stronger when considering just the 26 loci where a gene can be confidently 117 
implicated by fine-mapping to a coding variant or colocalisation with an eQTL (27% vs 3%, p=2x10-118 
5). In addition to PLCG2 we identified an association between Crohn’s disease and an intronic 119 
variant in NCF4 (P=1.76x10-8). This gene encodes p40phox, a component of the NADPH-oxidase 120 
system that is responsible for the oxidative burst in innate immune cells and which is a key 121 
mechanism of killing phagocytosed bacteria. Rare pathogenic variants in NCF4 cause autosomal 122 
recessive chronic granulomatous disease, characterized by Crohn’s disease-like intestinal 123 
inflammation and defective ROS production in neutrophils26. Our associated variant, rs4821544, had 124 
previously been suggestively associated with small bowel Crohn’s disease27,28, and when we 125 
stratified patients by disease location we found that the effect was consistently stronger for small 126 
bowel compared to large bowel disease (Supplementary Figure 7).  127 
Among the remaining 21 novel loci we noted three that were within 150kb of integrin genes (ITGA4, 128 
ITGAV and ITGB8), while a previously associated locus overlaps with a fourth integrin, ITGAL. 129 
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Furthermore, a recent study demonstrated that there is an IBD specific association that affects 130 
expression of ICAM1, which encodes the binding partner of ITGAL29. Integrins are cell adhesion 131 
mediators with bi-directional signalling capabilities that play a crucial role in leukocyte homing and 132 
cell differentiation in inflammation and cancer30. Given the strong candidacy of these genes, we 133 
sought potentially causal molecular mechanisms that would connect the IBD associated SNPs to 134 
integrin regulation. Our fine-mapping analysis excluded the possibility that these associations are 135 
caused by protein-coding changes, so we next tested for effects of IBD risk SNPs on integrin gene 136 
expression in immune cells using twelve publicly available eQTL datasets. While many eQTLs and 137 
GWAS signals show some degree of correlation, inferences about causality require more robust 138 
statistical co-localization of the two signals. Remarkably, we observed three of our five associations 139 
had >90% probability of being driven by the same variants as monocyte-specific stimulus response 140 
eQTLs (ITGA4, PLPS_24hr=0.984; ITGAL, PLPS_24hr=0.980; ICAM1, PLPS_2hr=0.961; Supplementary 141 
Table 5). A fourth association, ITGB8, is difficult to map due to extended linkage disequilibrium in the 142 
locus, but shows intermediate evidence of co-localization (PLPS_24hr=0.712) in response to the same 143 
stimulus (Figure 2). All four of the IBD risk increasing alleles upregulate expression of their 144 
respective genes, suggesting that increased levels of pro-inflammatory cell surface markers in 145 
response to stimulus may be a consistent mechanism of action. Proving this hypothesis would 146 
require showing that IBD risk alleles causally change stimulus-response expression (e.g. by targeted 147 
editing of each allele in cell lines homozygous for the low risk haplotype), and moreover that such 148 
changes have physiological relevance to disease processes.  149 
One line of evidence that supports such disease relevance for integrins and their counter-receptors 150 
is their recent emergence as important therapeutic targets in IBD. Most promisingly, the monoclonal 151 
antibodies vedolizumab and etrolizumab, which target the components of the α4β7 dimer (encoded 152 
by ITGA4 and ITGB7, and responsible for the gut-homing specificity of certain leukocytes), have 153 
demonstrated efficacy in IBD31–33. Additionally, an antisense oligonucleotide targeting ICAM1 has 154 
shown promise in the treatment of ulcerative colitis and pouchitis34. The importance of gut-selectivity 155 
for therapeutic approaches is highlighted by the antibodies that bind the αL and α4 integrin subunits 156 
(encoded by ITGAL and ITGA4, respectively). Therapies targeting αL (efalizumab) and α4 157 
(natalizumab) demonstrated potential in Crohn’s disease35,36, but both medications have been 158 
associated with progressive multifocal leukoencephalopathy (PML)37. This potentially fatal condition 159 
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is likely mediated by binding to integrin dimers that are not gut-specific, leading to impaired 160 
leukocyte migration to the central nervous system and JC virus infection of the brain. Owing to the 161 
risk of PML, efalizumab has been withdrawn from the market and natalizumab is not licensed for 162 
Crohn’s disease in Europe. 163 
Integrins are not only important in cell trafficking, but can also participate in cellular signalling. For 164 
example, the αVβ8 heterodimer – both subunits of which are encoded by genes which are now 165 
within confirmed IBD loci (ITGAV and ITGB8, respectively) – is a potent activator of TGFβ38, with a 166 
range of cell-type specific effects. Furthermore, mice with dendritic-cell specific deletion of this 167 
complex had impaired regulatory T cell function and severe colitis39, whereas deleting the complex in 168 
regulatory T cells themselves prevented them from suppressing pathogenic T cell responses during 169 
active inflammation40. While no current IBD therapeutics target αVβ8 directly, promising early results 170 
of an oral antisense oligonucleotide to the inhibitory TGFβ-signalling protein SMAD741, itself 171 
encoded by a locus identified by genetic association studies25, demonstrate the therapeutic potential 172 
of modifying TGFβ signaling in Crohn’s disease.  173 
In addition to the connections to anti-integrin and anti-TGFβ therapies described above, IBD GWAS 174 
have previously implicated loci containing other therapeutically relevant genes, such as those in 175 
signalling pathways relevant to the targets of anti-TNF and anti-p40 IBD therapies (Figure 3, 176 
Supplementary Table 6). These discoveries have demonstrated that the importance of the biological 177 
pathways underlying associations, and their potential therapeutic relevance, are not necessarily 178 
reflected in their GWAS effect sizes. For example, the modest odds ratios of the signals near integrin 179 
genes (1.10-1.12) required tens of thousands of samples to detect at genome-wide significance. 180 
Furthermore, analyses aimed at understanding the specific cellular contexts in which these genes 181 
are active in IBD, as well as the risk-increasing direction of effect (e.g. consistent up-regulation of 182 
integrins in response to LPS stimulus), are only beginning to bear fruit. 183 
Our study has demonstrated that continuing to pursue GWAS, even in a well studied complex 184 
disease like IBD, has the potential to complement other powerful approaches, such as targeted 185 
genotyping (via the Immunochip) and large-scale genome and exome sequencing. In two cases we 186 
have implicated genes in which different variants have previously been shown to cause immune-187 
related Mendelian disorders, echoing a connection made to the very first Crohn’s disease risk gene, 188 
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NOD2, in which rare missense mutations cause the autosomal dominant granulomatous disorder 189 
Blau syndrome42. Finally, while the individual effect sizes of our newly discovered associations are 190 
modest, our results show that GWAS continues to deliver new loci, which help understand many 191 
aspects of disease biology, including possible mechanisms of known therapies. For example, four 192 
IBD associations that plausibly co-localize with changes in integrin expression underscore the value 193 
of comprehensive catalogs of the regulatory consequences of GWAS variants in specific cells and 194 
contexts. Even when specific genes are implicated, cellular assays with relevance to disease 195 
physiology (for example, protein response to bacterial stimulus in colonic organoids) will be needed 196 
to achieve the ultimate payoff from prospectively mining these signals for promising targets for new 197 
therapeutics.  198 
Data availability 199 
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Figure legends 316 
 317 
Figure 1. Likely causal missense variants. For A) SLAMF8 and B) PLCG2, local association 318 
results are plotted with point size corresponding to LD to our lead variant and color to fine-mapping 319 
probability (purple > 50%, intermediate blue 10-50%, navy blue <10%). Gene body diagrams and 320 
protein domain annotations are taken from ENSEMBL, and partial predicted crystal structures for 321 
both proteins are obtained from the SWISS-MODEL repository. 322 
 323 
Figure 2.  Co-localization of disease association and stimulus response eQTLs in monocytes. 324 
The local pattern of disease association (IBD: (A) ITGA4, (B) ITGB8, (C) ICAM1; (D) UC: ITGAL) in 325 
grey, and the association of that variant with response to LPS (lipopolysaccharide) stimulation in red. 326 
Evidence of co-localization (probability > 70%) is observed for all for signals. 327 
 328 
Figure 3. IBD-associated loci containing genes in immune pathways related to classes of 329 
approved therapeutics. All IBD loci are divided into the studies where they were first identified1. 330 
Loci that contain a gene in one of four signalling pathways related to targets of three classes of 331 
approved IBD therapeutics (Online Methods) are highlighted, with those where the pathway gene 332 
has been confidently identified as the causal IBD gene labelled. Despite the general pattern that 333 
effect size decreases from left to right, therapeutically relevant associations continue to be found.334 
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Tables 335 
 336 
Table 1. Novel IBD-associated loci.  337 
Rsid Chr Position 
bp Left - right Mb Risk 
All
ele
No
n - 
ris
k 
All
ele
Risk Allele 
Frequency 
in 1000 
Genomes 
CEU+GBR
PMeta OR 95% CI Phenotype Implicated 
gene 
rs34687326 1 159799910 159.80 - 159.80 G A 0.900 1.06 x 10-08 1.18 1.12 - 1.24 CD SLAMF8
rs59043219 1 209970610 209.97 - 210.02 A G 0.379 1.09 x 10-08 1.08 1.05 - 1.10 IBD  - 
rs6740847 2 182308352 182.31 - 182.33 A G 0.508 1.22 x 10-13 1.10 1.07 - 1.12 IBD ITGA4
rs144344067 2 187576378 187.50 - 187.68 A AT 0.895 1.29 x 10-08 1.12 1.08 - 1.16 IBD  - 
rs1811711 2 228670476 228.67 - 228.67 C G 0.826 6.09 x 10-09 1.14 1.10 - 1.18 UC  - 
rs76527535 2 242484701 242.47 - 242.49 C T 0.745 2.87 x 10-08 1.09 1.06 - 1.12 IBD  - 
rs2581828 3 53133149 53.10 - 53.17 C G 0.597 6.46 x 10-09 1.10 1.07 - 1.13 CD  - 
rs2593855 3 71175495 71.16 - 71.19 C T 0.663 2.54 x 10-09 1.09 1.06 - 1.11 IBD  - 
rs503734 3 101023748 100.91 - 101.27 A G 0.513 2.67 x 10-08 1.07 1.05 - 1.10 IBD  - 
rs56116661 3 188401160 188.40 - 188.40 C T 0.795 5.67 x 10-10 1.14 1.10 - 1.18 CD  - 
rs11734570 4 38588453 38.58 - 38.59 A G 0.368 4.80 x 10-08 1.07 1.05 - 1.10 IBD  - 
rs17656349 5 149605994 149.59 - 149.63 T C 0.466 1.54 x 10-08 1.09 1.06 - 1.13 UC  - 
rs113986290 6 19781009 19.72 - 19.83 C T 0.989 7.59 x 10-09 1.36 1.25 - 1.46 UC  - 
rs67289879 6 42007403 42.00 - 42.01 T C 0.179 3.04 x 10-08 1.09 1.06 - 1.13 IBD  - 
rs11768365 7 6545188 6.50 - 6.55 A G 0.816 3.88 x 10-08 1.09 1.06 - 1.12 IBD  - 
rs149169037 7 20577298 20.58 - 20.58 G A 0.895 3.26 x 10-08 1.14 1.10 - 1.19 IBD ITGB8
rs243505 7 148435339 148.40 - 148.58 A G 0.624 3.04 x 10-10 1.08 1.06 - 1.11 IBD  - 
rs7911117 10 27179596 27.16 - 27.18 T G 0.871 1.84 x 10-08 1.14 1.10 - 1.19 UC  - 
rs111456533 10 126439381 126.32 - 126.55 G A 0.829 1.18 x 10-09 1.11 1.08 - 1.14 IBD  - 
rs80244186 13 42917861 42.84 - 42.94 C T 0.111 3.66 x 10-08 1.13 1.09 - 1.18 CD  - 
rs11548656 16 81916912 81.91 - 81.92 A G 0.961 5.18 x 10-11 1.27 1.20 - 1.34 IBD PLCG2
rs10492862 16 82867456 82.87 - 82.92 A C 0.308 1.26 x 10-09 1.11 1.08 - 1.15 CD  - 
rs4256018 20 6093889 6.08 - 6.10 G T 0.250 1.23 x 10-08 1.08 1.05 - 1.11 IBD  - 
rs138788 22 35729721 35.72 - 35.74 A G 0.418 2.95 x 10-08 1.09 1.06 - 1.13 UC  - 
rs4821544 22 37258503 37.26 - 37.26 C T 0.321 1.76 x 10-08 1.10 1.07 - 1.13 CD  - 
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Table 2. Variants fine-mapped to >50% probability of being causal in their given signal.  339 
Rsid Chr Position (bp) PCausal Effect Credible 
set size
Phenotype PMeta Locus 
type
rs34687326 1 159799910 1.000 SLAMF8 
p.Gly99Ser 
(missense)
1 CD 1.06 x 10-08 Novel
rs4845604 1 151801680 0.999 RORC 
(intronic)
1 IBD 7.09 x 10-14 Known
rs1811711 2 228670476 0.914  2 UC 6.09 x 10-09 Novel
rs56116661 3 188401160 0.561 LPP (intronic) 11 CD 5.67 x 10-10 Novel
rs11548656 16 81916912 0.502 PLCG2 
p.His244Arg 
(missense)
3 IBD 5.18 x 10-11 Novel
rs1143687 16 81922813 0.746 PLCG2 
p.Arg268Trp 
(missense)
5 IBD 3.83 x 10-08 Novel
rs4821544 22 37258503 0.804  NCF4 
(intronic)
2 CD 1.76 x 10-08 Novel
  340 
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Online Methods 341 
 342 
New genome-wide genetic data 343 
GWAS samples and genotyping. Following ethical approval by Cambridge MREC (reference: 344 
03/5/012), 11,768 British IBD cases, diagnosed using accepted endoscopic, histopathological and 345 
radiological criteria, were consented into the study and genotyped on the Human Core Exome v12.1. 346 
10,484 population control samples genotyped on the Human Core Exome v12.0 were obtained from 347 
the Understanding Society Project. Genotypes were called using optiCall43. 348 
GWAS quality control. We removed variants that did not overlap between the two versions of the 349 
chip, had missingness > 5%, a significant difference in call rate between cases and controls (P < 350 
1x10-5), deviated from Hardy-Weinberg equilibrium (HWE) in controls (P < 1x10-5), or that were 351 
affected by a genotyping batch effect (significant association [P < 1x10-5] between an outlier group of 352 
cases discovered using principal component analysis [PC1 < -0.005], and the remainder of the 353 
samples). We then removed samples with missingness > 1%, heterozygosity ±3 standard deviations 354 
from the mean, mismatch between reported and genotypic sex, first-degree relatives or closer 355 
(kinship coefficient > 0.177), and non-European samples identified through principal component 356 
analysis with HapMap3 populations. After quality control, data were available for 4,474 Crohn’s 357 
disease, 4,173 ulcerative colitis, 592 IBD-unclassified cases and 9,500 controls for 296,203 variants. 358 
Whole-genome sequenced samples. We generated low-coverage whole genome sequences for 359 
4,686 IBD cases and 3,781 population controls from the UK IBD Genetics Consortium (UKIBDGC) 360 
and UK10K Consortium, respectively. Detailed information on sequencing, genotype refinement and 361 
quality control are described elsewhere9. 362 
Imputation. These sequences were combined with 2,504 samples from the Phase 3 v5 release of 363 
the 1000 Genomes project (2013-05-02 sequence freeze) to create a phased imputation reference 364 
panel enriched in IBD-associated variants. We used PBWT44 to impute from this reference panel 365 
(114.2 million total variants) into our new GWAS described above. 366 
  367 
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Association testing, meta-analysis, and quality control. 368 
Association testing. Prior to association testing, we removed all samples that were included in 369 
previous IBD GWAS meta-analyses (Supplementary Table 1). We then tested for association to 370 
ulcerative colitis, Crohn’s disease and IBD separately within the sequenced samples and new 371 
GWAS using SNPTEST v2.5, performing an additive frequentist association test conditioned on the 372 
first ten principal components for each cohort. We filtered out variants with minor allele frequency 373 
(MAF) < 0.1%, INFO < 0.4, or strong evidence for deviations from HWE in controls (pHWE<1x10-7). 374 
Meta-analysis. We used METAL (release 2011-03-05) to perform a standard error weighted meta-375 
analysis of our sequencing and GWAS cohorts with the publicly available International Inflammatory 376 
Bowel Disease Genetics Consortium (IIBDGC) meta-analysis summary statistics1, after applying the 377 
additional MAF ≥ 0.1%, and INFO ≥	0.4 filters to the IIBDGC data. 378 
Quality control. The output of the fixed-effects meta-analysis was further filtered, and sites with high 379 
evidence for heterogeneity (I2>0.90) were discarded. Only sites for which all cohorts passed our 380 
quality control filters were included in our analysis. In addition, we discarded genome-wide 381 
significant variants for which the meta-analysis p-value was not lower than all of the cohort-specific 382 
p-values. 383 
LD score regression. We performed LD score regression using LDSC v1.0.0 and European linkage 384 
disequilibrium (LD) scores from the 1000 Genomes Project (downloaded from 385 
https://data.broadinstitute.org/alkesgroup/LDSCORE/eur_w_ld_chr.tar.bz2) on our filtered meta-386 
analysis summary statistics for all sites with INFO > 0.95. This INFO threshold is to avoid 387 
confounding due to poor imputation, as recommended by the authors45. 388 
Locus definition 389 
Computing LD windows. An LD window was calculated for every genome-wide significant variant in 390 
any of the three traits (Crohn’s disease, ulcerative colitis, IBD), defined by the left-most and right-391 
most variants that are correlated with the main variant with an r2 of 0.6 or more. The LD was 392 
calculated in the GBR and CEU samples from the 1000 Genomes Phase 3, release v5 (based on 393 
20130502 sequence freeze and alignments). Loci with overlapping LD windows, as well as loci 394 
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whose lead variants were separated by 500kb or less, were subsequently merged, and the variant 395 
with the strongest evidence of being associated was kept as the lead variant for each merged locus. 396 
Identifying novel loci. A locus was annotated as known if it contained at least one variant previously 397 
reported at genome-wide significance (irrespective of the LD between that variant and the most 398 
associated variants in the locus). To ensure that putatively novel signals were not due to long-range 399 
LD with variants in previously reported loci, we conducted conditional analysis in our new GWAS for 400 
all variants in loci which were less than 3Mb away from a known locus. Putatively novel loci already 401 
known in a lower order IBD trait (e.g. a previously known Crohn’s disease locus coming up as an 402 
IBD locus) were also removed from this list. This did not apply where, for example, a known Crohn’s 403 
disease locus was now associated with ulcerative colitis, or vice versa. 404 
Fine-mapping 405 
Approximate Bayes factors were calculated from the meta-analysis effect sizes and standard errors 406 
described above by applying equation (2) of Wakefield46, assuming a prior variance on the log odds 407 
ratios of 0.04 (the default prior used by the software SNPTest, and used by Maller et al47). We then 408 
performed fine-mapping using these Bayes factors as described in Maller et al to calculate the 409 
posterior that each variant is causal, and the 95% credible set for each association (the smallest set 410 
of variants with posteriors that sum to at least 95%). For each association we use the meta-analysis 411 
results for the phenotype (Crohn’s disease, ulcerative colitis or IBD) specified in Supplementary 412 
Table 2. We only consider a locus to be confidently fine-mapped if there are no variants in the Phase 413 
3 v5 release of the 1000 Genomes project (2013-05-02 sequence freeze) in high LD (r2 ≥0.6) with 414 
our hit SNP, but missing from our dataset, and no variants in our data within high LD (r2 > 0.8) that 415 
fail during our QC procedure. 416 
eQTL overlap 417 
Identifying eQTL overlaps. Twelve eQTL datasets were searched to identify variants within the 25 418 
newly identified IBD risk loci that are associated with variation in gene expression (Supplementary 419 
Table 7). Splice-QTLs based on exon-ratio48 and transcript-ratio49–51 were also included in the 420 
search where available (Supplementary Table 7). The most significant variant-gene associations 421 
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were extracted from each eQTL/splice-QTL dataset and were reported as candidates if that variant 422 
had r2 > 0.8 with any of the lead SNPs in the 25 IBD risk loci. 423 
Testing for co-localization. We tested for co-localization between IBD association signals and eQTLs 424 
using the coloc2 method52, implemented in the R package coloc. We used a window size of 250kb 425 
on either side of the IBD association, and implemented the default settings as recommended. Each 426 
test was repeated using two different values for the prior probability of co-localization, p12: 1x10-5 and 427 
1x10-6. 428 
Signalling pathway definitions 429 
We identify the following immune pathways as relevant to classes of approved IBD therapeutics: the 430 
IL12 and IL23 signalling pathways (ustekinumab53), the TNFa signalling pathway (infliximab54, 431 
adalimumab55), and the integrin signalling pathway (vedolizumab31,32). Genes involved in these 432 
pathways were identified from the Molecular Signatures Database canonical pathways gene sets 433 
(C2; http://software.broadinstitute.org/gsea/msigdb/genesets.jsp?collection=CP). These gene lists 434 
had been previously curated by the Pathway Interaction Database56. The integrin signalling gene list 435 
was comprised of all unique genes from the following gene sets: integrin beta1 pathway 436 
(PID_INTEGRIN1_PATHWAY), integrin beta7 pathway (PID_INTEGRIN5_PATHWAY) and integrin 437 
cell surface interactions (PID_INTEGRIN_CS_PATHWAY). The list of TNFa signalling genes was 438 
obtained from PID_TNF_PATHWAY and the list of IL-23/IL-12 p40 signalling genes was comprised 439 
of all unique genes from the PID_IL12_PATHWAY and PID_IL23_PATHWAY.  440 
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